Insulet Corporation $PODD Shares Acquired by Vanguard Personalized Indexing Management LLC

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Insulet Corporation by 15.0%, owning 15,653 shares valued at approximately $4.92 million after acquiring additional shares in the 2nd quarter.
• Insulet's stock has received several upgrades from analysts, with target prices raised by firms like Canaccord Genuity and Wells Fargo, alongside a predominantly positive consensus rating of "Moderate Buy."
• Recent insider transactions include sales by senior vice presidents, with significant decreases in their holdings, indicating possible changes in confidence among company executives.

Vanguard Personalized Indexing Management LLC increased its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 15.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,653 shares of the medical instruments supplier's stock after purchasing an additional 2,043 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Insulet were worth $4,918,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Nissay Asset Management Corp Japan ADV lifted its holdings in Insulet by 0.6% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock valued at $2,222,000 after acquiring an additional 48 shares during the last quarter. Mather Group LLC. lifted its holdings in Insulet by 4.4% in the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier's stock valued at $360,000 after acquiring an additional 48 shares during the last quarter. Brooklyn Investment Group lifted its holdings in Insulet by 7.0% in the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock valued at $209,000 after acquiring an additional 52 shares during the last quarter. Cooper Financial Group lifted its holdings in Insulet by 5.7% in the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock valued at $283,000 after acquiring an additional 58 shares during the last quarter. Finally, HighTower Advisors LLC lifted its holdings in Insulet by 2.1% in the 1st quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier's stock valued at $757,000 after acquiring an additional 60 shares during the last quarter.

Insider Transactions at Insulet

In other news, SVP Prem Singh sold 687 shares of the company's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Laetitia Cousin sold 797 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Citigroup reissued a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Canaccord Genuity Group upped their price objective on shares of Insulet from $353.00 to $399.00 and gave the company a "buy" rating in a research note on Monday, September 29th. Barclays upped their price objective on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Wells Fargo & Company upped their price objective on shares of Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. Finally, Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $347.67.

Insulet Price Performance

Shares of PODD opened at $314.56 on Tuesday. The company has a market capitalization of $22.14 billion, a price-to-earnings ratio of 95.61, a P/E/G ratio of 2.61 and a beta of 1.40. Insulet Corporation has a fifty-two week low of $226.50 and a fifty-two week high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The business's 50-day moving average is $324.28 and its 200-day moving average is $301.03.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm's quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.